Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Completed · Phase 2

Conditions studied: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia

In brief

This phase II trial studies how well sirolimus and azacitidine works in treating patients with high-risk myelodysplastic syndrome or recurrent acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sirolimus and azacitidine may kill more cancer cells.

Key facts

Study ID: NCT01869114
Run by: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
People needed: 57
Starts: 2013-07-08
Expected to finish: 2024-01-03
Last updated by the study team: 2025-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have a diagnosis of one of the following:
MDS (Arm A): High-risk MDS defined as: >5% blasts in bone marrow and/or the following cytogenetic categories: presence of inv(3)/t(3q)/del(3q), -7/del(7q), complex cytogenetics (3 or more abnormalities)
AML (Arm B): Relapsed/refractory/unable to tolerate conventional chemotherapy
MDS or AML as above BUT with prior therapy with Azacitibine (Arm C): Patients who meet criteria for either Arm A or Arm B but have been treated or are currently treated with Azacitibine *Note: As of July 2018, only high risk MDS patients will be eligible as Arm B is closed. As of October 2017, those patients with MDS who have received prior treatment will now be enrolled in Arm A as Arm C is closed.
Patients must be ≥ 18 years old
Patients must have an ECOG performance status of <= 2 (see Attachment 1).
Patients must have a life expectancy of at least 4 weeks.
Patients must be able to consume oral medication.
Patients must have completed any radiotherapy four weeks prior to study entry, 0-2 weeks for local palliative XRT (small port).
Patients must have recovered from the toxic effects of any prior chemotherapy to < Grade 2 (except for alopecia).
Required initial laboratory values: Creatinine≤ 2.0mg/dL; total or direct bilirubin ≤ 1.5mg/dL (if not due to the leukemia itself or known Gilbert's Syndrome);(as documented by treating physician) SGPT(ALT) ≤ 3xULN; glucose <200 mg/dL, negative pregnancy test for women of child-bearing potential.
Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
Patients may have had a prior stem cell transplant (autologous or allogeneic), however they may not have active GvHD, nor be on any immunosuppression

You may not qualify if…

Patients must not be receiving any chemotherapy agents (except Hydroxyurea)
Intrathecal ARA-C and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system).
Patients can not have received more than 3 prior lines of therapy for their hematologic malignancy. Patient may have previously had azacitidine or decitabine will be eligible to enroll on Arm A (MDS)
Patients must not be receiving growth factors.
Patients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible. If a patient has had a prior second malignancy that is not currently requiring active treatment, the patient will be considered eligible.
Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.
Patients may not take any of the following medications while on study, but will be considered eligible if medication is discontinued 72 hrs prior to first dose of Sirolimus:
Carbamazepine (e.g. Tegretol)
Rifabutin (e.g. Mycobutin)
Rifampin (e.g. Rifadin)
Rifapentine (e.g. Priftin)
St. John's Wort- may decrease effects of sirolimus by decreasing the amount of sirolimus in the body
Clarithromycin (e.g. Biaxin)
Cyclosporin e.g. (Neoral or Sandimmune)
Diltiazem (e.g. Cardizem)
Erythromycin (e.g. Akne-Mycin, Ery-Tab)
Itraconazole (e.g. Sporanox)
Fluconazole (e.g. Diflucan)
Ketoconazole (e.g. Nizoral)
Telithromycin (e.g. Ketek)
Verapamil (e.g. Calan SR, Isoptin, Verelan)
Voriconazole (e.g. VFEND) - May increase the effects of sirolimus by increasing the amount of this medicine in the body. Can take 72 hours after last dose of Sirolimus
Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus.
Patients with known HIV positivity or AIDS-related illness are not eligible.
Patients with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.

Where it is running

Jefferson Health NJ Division (Kennedy Hospital) — Sewell, New Jersey, United States
Abington Hospital - Jefferson Health — Abington, Pennsylvania, United States
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania, United States
Jefferson Health, Aria Hospital — Philadelphia, Pennsylvania, United States
Jefferson Health, Methodist Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.